LIVZON PHARMAC. GRP H YC1 Market Cap ($890.29 Million)
Market Cap & Net Worth: LIVZON PHARMAC. GRP H YC1 (LP6)
LIVZON PHARMAC. GRP H YC1 market cap. LIVZON PHARMAC. GRP H YC1 (F:LP6) has a market capitalization of $890.29 Million (€761.51 Million) as of November 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #9024 globally and #1163 in its home market, demonstrating a 15.45% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LIVZON PHARMAC. GRP H YC1's stock price €2.54 by its total outstanding shares 299807117 (299.81 Million). Also see LIVZON PHARMAC. GRP H YC1 (LP6) cash flow conversion for how efficiently the company converts equity into cash flow.
LIVZON PHARMAC. GRP H YC1 Market Cap History (2015–2026)
LIVZON PHARMAC. GRP H YC1 market cap history from 2015 to 2026. Data shows growth from $3.96 Million to $890.29 Million (62.56% CAGR). Check today's stock price for LIVZON PHARMAC. GRP H YC1 for real-time trading data and today's change.
LIVZON PHARMAC. GRP H YC1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LIVZON PHARMAC. GRP H YC1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore LP6 net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.09x
LIVZON PHARMAC. GRP H YC1's market cap is 0.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.54x
LIVZON PHARMAC. GRP H YC1's market cap is 0.54 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $114.72 Million | $12.06 Billion | $1.78 Billion | 0.01x | 0.06x |
| 2022 | $233.05 Million | $12.63 Billion | $1.91 Billion | 0.02x | 0.12x |
| 2023 | $462.35 Million | $12.43 Billion | $1.95 Billion | 0.04x | 0.24x |
| 2024 | $1.16 Billion | $11.81 Billion | $2.06 Billion | 0.10x | 0.56x |
| 2025 | $1.10 Billion | $12.02 Billion | $2.02 Billion | 0.09x | 0.54x |
Competitor Companies of LP6 by Market Capitalization
Companies near LIVZON PHARMAC. GRP H YC1 in the global market cap rankings as of November 3, 2026. Also see LIVZON PHARMAC. GRP H YC1 total assets for a full breakdown of the balance sheet.
Key companies related to LIVZON PHARMAC. GRP H YC1 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.59 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of LIVZON PHARMAC. GRP H YC1 (2015–2026)
Market capitalization of LIVZON PHARMAC. GRP H YC1 from 2015 to today. Between 2015 and today, LIVZON PHARMAC. GRP H YC1's market cap moved from $3.96 Million to $ 890.29 Million, with a yearly change of 62.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €890.29 Million | -19.11% |
| 2025 | €1.10 Billion | -4.85% |
| 2024 | €1.16 Billion | +150.17% |
| 2023 | €462.35 Million | +98.39% |
| 2022 | €233.05 Million | +103.15% |
| 2021 | €114.72 Million | +64.72% |
| 2020 | €69.65 Million | +66.83% |
| 2019 | €41.75 Million | +160.61% |
| 2018 | €16.02 Million | +58.68% |
| 2017 | €10.09 Million | +71.43% |
| 2016 | €5.89 Million | +48.67% |
| 2015 | €3.96 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 2nd, 2026 the market cap of LIVZON PHARMAC. GRP H YC1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $890.29 Million USD |
| MoneyControl | $890.29 Million USD |
| MarketWatch | $890.29 Million USD |
| marketcap.company | $890.29 Million USD |
| Reuters | $890.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LIVZON PHARMAC. GRP H YC1
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, il… Read more